Protagonist Therapeutics, Inc. PTGX
At closeNov 6, 2026, 4:50 PM EST
After hours · Nov 6, 4:50 PM ET
- YTD
- +51.18%
- 1 year
- +65.51%
- Market cap
- 8.54B
- Revenue (ttm)
- 551.69M
- Profit margin
- 62.04%
- EPS (ttm)
- 1.03
- Shares out
- 64.71M
- P/E ratio
- 128.19
- Forward P/E
- -1330.24
- YTD return
- +51.18%
- 1-year return
- +65.51%
- Volume
- 972.95K
- Avg volume
- 647.63K
- Open
- 135.26
- Previous close
- 135.26
- Day's range
- 128.00 – 138.40
- 52-week range
- 79.54 – 158.62
- Analysts
- Strong Buy
- Price target
- 178.57 (+35.2%)
- Earnings date
- Feb 24, 2027
YTD +44.86 (+51.46%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 15.49
- Price / book
- 13.44
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 5723.60%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 18.49%
- 50-day average
- 141.87
- 200-day average
- 117.74
Analyst view
Consensus: strong buy
- Target (low)
- 149.00
- Target (mean)
- 178.57
- Target (high)
- 225.00
- Strong buy3
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate -0.50438.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | -0.3206 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 2.50 | 3.07 | +0.57 | +22.80% |
| Aug 5, 2026 | Jun 30, 2026 | 2.23 | 2.29 | +0.06 | +2.69% |
| May 5, 2026 | Mar 31, 2026 | -0.65 | 0.05 | +0.70 | +107.69% |
| Feb 25, 2026 | Dec 31, 2025 | -0.53 | -0.69 | -0.16 | -30.19% |
| Nov 6, 2025 | Sep 30, 2025 | -0.59 | -0.62 | -0.03 | -5.08% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 21, 2026 | TD Cowen | main | Buy | Buy |
| Oct 12, 2026 | UBS | init | — | Buy |
| Sep 1, 2026 | Barclays | main | Overweight | Overweight |
| Sep 1, 2026 | BMO Capital | main | Outperform | Outperform |
| Aug 31, 2026 | Citigroup | main | Buy | Buy |
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- protagonist-inc.com
News
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221 - TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160
Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today 
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184 
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190
Your note
Sign in to keep a note on PTGX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALI ASIF | Chief Financial Officer | Sale | Apr 19, 2026 | 59,003 |
| GIRAUDO BRYAN M. | Director | Sale | May 7, 2026 | 0 |
| GUPTA SUNEEL | Officer | Sale | Nov 25, 2024 | 267,433 |
| MOLINA ARTURO MD | Officer | Sale | Mar 25, 2026 | 84,115 |
| O DOWD SARAH A | Director | Stock Award(Grant) | Jan 1, 2026 | 7,825 |
| PATEL DINESH V | Chief Executive Officer | Sale | Sep 9, 2026 | 522,968 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.93% | 10,307,837 | 1.36B | Jun 29, 2026 |
| Farallon Capital Management LLC | 9.81% | 6,348,906 | 838.31M | Jun 29, 2026 |
| RTW Investments LP | 7.82% | 5,061,175 | 668.28M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.61% | 3,629,298 | 479.21M | Jun 29, 2026 |
| Wellington Management Group, LLP | 5.28% | 3,416,781 | 451.15M | Jun 29, 2026 |
| UBS Group AG | 5.25% | 3,399,221 | 448.83M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.96% | 3,854,840 | 508.99M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 2,044,938 | 270.01M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.46% | 1,594,175 | 210.49M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 1,475,422 | 194.81M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.92% | 1,243,618 | 164.21M | Jul 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.57% | 1,013,552 | 133.83M | Sep 29, 2026 |